FinalDose
Programmable DNA drug destroying all cancers, unlocking 80% of targets
About FinalDose
FinalDose is building the first programmable drug - a single smart drug molecule that you can insert any diseased genetic code and it can search and destroy cells upon DNA recognition. Unlocking 80% of undruggable targets today. Starting with all cancers.
Company details
Funding
Last stage
Seed
Investors
Founders
Li-Yao Huang
DPhil in Biochemistry from Oxford. Spent 5+ years as a postdoctoral researcher at the MRC Weatherall Institute of Molecular Medicine. Led CRISPR screening projects on cancer targets; research focuses on BRCA1-deficient cancers and PARP inhibitor resistance.
Steven Lin
Oxford PhD in Computational Biology (Wellcome Trust scholarship). Previously Data Lead at Gutsee Biotech. Developed ML methods using coevolution biology to identify drug resistance targets in viruses; led UK Biobank analysis of genetic susceptibility during SARS-CoV-2.
LinkedInJeff Liu
CEO @ FinalDose (YC P26). Oxford PhD in Oncology. Previous startup (Vivid Dx) solved a multi-decade bottleneck in sepsis diagnostics: low biomass isolation. By overcoming this hurdle, we built the world’s fastest diagnostic system - slashing wait times from 5 days to just 30 minutes. Raised $15M in venture backing.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.